Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Obtain key information regarding the latest in pharmaceutical research from Informa Pharma Intelligence.
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects (which you can still access below). Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Examine the most successful new active substances (NASs) that hit the market for the first time in 2017. Find out:
Pharmaprojects’ analysts have compiled a compelling view of R&D, past, present, and future. Download your free report today, and discover:
A total pipeline overview, including an overview by phase
Which companies have the most drugs currently in the pipeline
The top therapeutic focus in R&D pipelines
A view of the types of drugs in the pipeline – are biologics the wave of the future?
The top mechanisms of action and targets of investigation
Outlook for the future: what’s in store?
In Vivo
By William Looney 27 Jan 2020
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
Pink Sheet
By Vibha Sharma 27 Jan 2020
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.
HBW Insight
By Malcolm Spicer 27 Jan 2020
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
HBW Insight
By Tom Gallen 27 Jan 2020
Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.
Generics Bulletin
By David Wallace 27 Jan 2020
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
Generics Bulletin
By Aidan Fry 27 Jan 2020
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Topic Biosimilars Deal trends
Medtech Insight
By Amanda Maxwell 27 Jan 2020
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.
Medtech Insight
By Brian Yang 27 Jan 2020
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.
Scrip
By Daniel Chancellor 27 Jan 2020
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
Scrip
By Brian Yang 27 Jan 2020
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Skipta
27 Jan 2020
In combating ad blindness and ad-blocking, this whitepaper explains how thoughtful, relevant messages, aimed at carefully-segmented audiences, can be delivered through channels that audiences trust and engage with.
Topic Digital Health
Scrip
By Mandy Jackson 22 Jan 2020
Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.
Skipta
17 Jan 2020
Explore the challenges in digital marketing that can make it difficult for you to directly connect with your specific target audience. Let Skipta’s exclusive perspectives be your guide.
Pink Sheet
By Brenda Sandburg 16 Jan 2020
An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.
Topic FDA Policy and regulation
Pink Sheet
12 Dec 2019
Scrip
12 Dec 2019
Pink Sheet
12 Dec 2019
In Vivo
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
Pink Sheet
12 Dec 2019
Pink Sheet
12 Dec 2019
In Vivo
12 Dec 2019
Pink Sheet
12 Dec 2019
Pink Sheet
12 Dec 2019
Medtech Insight
12 Dec 2019
Pink Sheet
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Key benefits:
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
